Abt 263

Manufactured by Apexbio

Sourced in United States

ABT-263 is a small molecule that inhibits the activity of the BCL-2 family of proteins. It is commonly used in research applications to study apoptosis and cancer cell biology.

Automatically generated - may contain errors

Lab products found in correlation

18 protocols using abt 263

Evaluating Senolytic Drugs on HGPS Fibroblasts

Check if the same lab product or an alternative is used in the 5 most similar protocols

Primary human dermal fibroblasts derived from an HGPS donor were obtained from The Progeria Research Foundation Cell and Tissue Bank and cultured in Dulbecco’s modified Eagle medium (Invitrogen), supplemented with 10% v/v fetal bovine serum (FBS; Invitrogen) and 1% v/v Penicillin-Streptomycin (Invitrogen). Before reaching complete confluence, cells were expanded using 0.25% Trypsin/EDTA (Gibco), followed by inactivation of the enzyme using FBS-containing medium. Primary human dermal fibroblasts derived from healthy donors were purchased from Coriell Institute for Medical Research and maintained in the same conditions.
ABT-263 (ApexBio, final concentration: 1.25 or 5 μM) or Rapamycin (Fisher Scientific, final concentration 100 nM) were added to cell culture media of fibroblasts for 2D assays and maintained for 3 days. Samples were collected for analysis after three days of recovery following ABT-263 or Rapamycin removal.

Boroni M., Zonari A., Reis de Oliveira C., Alkatib K., Ochoa Cruz E.A., Brace L.E, & Lott de Carvalho J. (2020). Highly accurate skin-specific methylome analysis algorithm as a platform to screen and validate therapeutics for healthy aging. Clinical Epigenetics, 12, 105.

+ Open protocol

+ Expand

ABT 263 Treatment in Aged Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

For drug treatments, 22- to 24-month-old male C57BL/6 mice from the National Institute on Aging (Bethesda, MD, USA) were treated with vehicle or ABT 263 (APExBIO, USA) diluted in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG (Lipoid, Germany). ABT 263 was administered by oral gavage at 50 mg per kg body weight per day (mg/kg/day) for 7 days per cycle for two cycles with a 2-week interval between the cycles.

Mehdipour M., Mehdipour T., Skinner C.M., Wong N., Liu C., Chen C.C., Jeon O.H., Zuo Y., Conboy M.J, & Conboy I.M. (2020). Plasma dilution improves cognition and attenuates neuroinflammation in old mice. GeroScience, 43(1), 1-18.

+ Open protocol

+ Expand

Compound Library Screening for Autophagy Modulators

Check if the same lab product or an alternative is used in the 5 most similar protocols

Paclitaxel was obtained from Calbiochem (Merck Millipore, Billerica, MA, USA). ABT-263 and BV6 for in vitro use were purchased by APEX Bio (Houston, TX, USA). The custom-made library of 320 small molecule compounds was purchased by Selleck Chemicals (Houston, TX, USA). Rabbit polyclonal anti-human LC3 (1:1,000) was kindly provided by Prof. Z. Elazar (Weizmann Institute of Science). Mouse monoclonal p62/SQSTM1 antibody (clone 2C11; 1:1,000) was purchased from Novus Biologicals (Littleton, CO, USA). Mouse monoclonal anti-human ATG5 (clone ATG5-18; 1:3,000) was purchased from Sigma. Mouse monoclonal anti-human GAPDH antibody (clone 6C5; 1:1,000) was obtained from EMD Millipore (Darmstadt, Germany).

Panayotopoulou E.G., Müller A.K., Börries M., Busch H., Hu G, & Lev S. (2017). Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells. Oncotarget, 8(28), 45088-45104.

+ Open protocol

+ Expand

Glioblastoma Cell Culture and Treatments

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cultures of patient-derived TS13-18 and TS13-20 cells has been described previously [30 (link)]. Briefly, both cell lines were established directly from male patients with IDH1 (Isocitrate dehydrogenase 1) wild-type primary World Health Organization (WHO) grade 4 glioblastomata. While the MGMT (O⁶-alkylguanine DNA alkyltransferase) gene promoter in TS13-18 was unmethylated, the same promoter in TS13-20 was methylated. Glioblastoma TS cells and their differentiated counterparts were cultured as previously described [30 (link)]. Briefly, TS cells were cultured in growth media at 37 °C in a 5% CO₂ humidified incubator. The differentiated counterparts were cultured under the same conditions but supplemented with 10% heat-inactivated fetal bovine serum (FBS; #SH30084.03; HyClone, Logan, UT, USA). Growth media consisted of DMEM/F-12 (#10-0900cv; HyClone) supplemented with 1× B27 (#17504-044; Invitrogen, San Diego, CA, USA), 20 ng/mL basic fibroblast growth factor (#E0291; Sigma–Aldrich, St. Louis, MO, USA), 20 ng/mL epidermal growth factor (#E9644; Sigma–Aldrich), and 1% penicillin-streptomycin (#15140-122; Invitrogen). Gossypol (#G8761) and TMZ (#T2577) were purchased from Sigma–Aldrich and ABT-263 (#A3007) was obtained from APExBIO (Boston, MA, USA).

Kim H.Y., Lee B.I., Jeon J.H., Kim D.K., Kang S.G., Shim J.K., Kim S.Y., Kang S.W, & Jang H. (2019). Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres. Biomolecules, 9(10), 595.

+ Open protocol

+ Expand

Combination Therapy for PDX Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tumors were established from dissociated PDX and tumor harboring mice were randomized into treatment and control cohorts of 6 animals when the tumor average size reached about 100 mm³. ABT-263 (ApexBio, A3007) was dissolved in a mixture of 10% EtOH, 30% PEG-400 (Lipoid) and 60% phosal 50 PG (Sigma Aldrich) and was given orally (100 mg/kg) alone or 1.5 h after standard chemotherapy in combination experiments. Compound solution was prepared fresh before drug administration and any remaining solution was routinely stored at +4°C for no longer than 1 wk. Vincristine (Teva) was injected intravenously (i.v.) (0.5 mg/kg). Tumor size was measured 3 times a wk using a caliper and mouse weight was measured twice a wk. No mice needed to be euthanized due to severe body weight loss (>20% than baseline). All animal experiments were performed under license of the authorities of the Kt. Zürich (206/15).

Manzella G., Moonamale D.C., Römmele M., Bode P., Wachtel M, & Schäfer B.W. (2021). A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors. Neoplasia (New York, N.Y.), 23(9), 929-938.

+ Open protocol

+ Expand

Apoptosis Induction and Mitochondrial ROS

Check if the same lab product or an alternative is used in the 5 most similar protocols

Without specific indication, the reagents obtained from Sigma-Aldrich Inc. (St. Louis, MO, USA) were used in this study, and cell culture supplements were the products of GIBCO/Life Technologies Inc. (Carlsbad, CA, USA). ABT-263 was obtained from Apexbio Technology LLC (Houston, TX, USA), and A-1210477 was the product of MedChem Express (Monmouth Junction, NJ, USA). MitoSOX Red, tetramethylrhodamine (TMRM), annexin V-FITC/propidium iodide (PI) apoptosis detection kit, and dichlorodihydrofluorescein diacetate (H₂DCFDA) were obtained from Molecular Probes (Eugene, OR, USA); and Z-DEVD-FMK was from Calbiochem (San Diego, CA, USA).

Wang L.J., Liou L.R., Shi Y.J., Chiou J.T., Lee Y.C., Huang C.H., Huang P.W, & Chang L.S. (2020). Albendazole-Induced SIRT3 Upregulation Protects Human Leukemia K562 Cells from the Cytotoxicity of MCL1 Suppression. International Journal of Molecular Sciences, 21(11), 3907.

+ Open protocol

+ Expand

Colon Cancer Cell Treatment Protocol

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

SW48 colon cancer cells (ATCC – CCL-231) were maintained in RPMI-1640 (Gibco) supplemented with 10% fetal bovine serum (FBS) (#TMS-013-B, Millipore) and 1% penicillin-streptomycin (#15070, Gibco). Cells were grown at 37°C in 5%

{CO}_{2}

and passaged at 70% confluency. For all experiments, a treatment of 250-nM ABT-263 (ApexBio cat# A3007), 10-nM TAK-228 (LC Laboratories cat.# I-3344), or the combination was used. These doses are based on physiologically relevant blood serum levels of ABT-263³⁷ (link)^,³⁸ (link) and on a WST-1 dose response curve for TAK-228, where 10 nM was shown to decrease proliferation of cells by

> 50 %

compared to control.³⁹ (link) Cells were exposed to treatment for 24 h.

Gillette A.A., DeStefanis R.A., Pritzl S.L., Deming D.A, & Skala M.C. (2022). Inhibition of B-cell lymphoma 2 family proteins alters optical redox ratio, mitochondrial polarization, and cell energetics independent of cell state. Journal of Biomedical Optics, 27(5), 056505.

+ Open protocol

+ Expand

Apoptosis Induction Pathway Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fenretinide, ABT-263, and Q-VD-OPh were purchased from ApexBio Tech (Houston, TX). Antibodies for BIM, BAX, BAK, BCL-X_L, Cleaved-PARP (Asp214), Cleaved-Caspase3, GAPDH (D16H11), HRP-linked Anti-Rabbit IgG, HRP-linked anti-mouse IgG, and Anti-Rabbit IgG conformation-specific antibodies were from Cell Signaling Technology (Beverly, CA); NOXA (114C307.1) was from Thermo Fisher Scientific (Waltham, MA); MCL-1 (ADI-AAP-240-F) was from Enzo Life Sciences (Farmingdale, NY); BCL-2 (100) was from Sigma-Aldrich. BAK antibodies for immunoprecipitation were purchased from Sigma-Aldrich (06–536 and AM03). ECL2 Western blotting substrate was purchased from Thermo Fisher Scientific (Rockland, IL). Annexin V-FITC and Annexin V-APC were purchased from Biolegend (San Diego, CA) and Thermo Fisher Scientific, respectively. Propidium Iodide was purchased from Sigma-Aldrich.

Britt E.L., Raman S., Leek K., Sheehy C.H., Kim S.W, & Harada H. (2019). Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment. PLoS ONE, 14(7), e0219398.

+ Open protocol

+ Expand

Cell Line Maintenance and Drug Treatments

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

All cell lines were maintained in high-glucose DME media supplemented with 10% fetal bovine serum, 2 mM glutamine, and 100 U/mL penicillin/streptomycin. The TS1 cell line was derived in J.A.J.’s laboratory as previously reported (Shree et al., 2011 (link)). CAF1 and AdAF lines were provided by Dr. Erik Sahai (Calvo et al., 2013 (link)). EOMA and C166 cell lines were purchased from the ATCC (Obeso et al., 1990 (link); Wang et al., 1996 (link)). Where indicated, 50 nM Taxol (Sigma), 50 μM carboplatin (Selleckchem), 300 nM doxorubicin (Selleckchem), 20 μM etoposide (Selleckchem), 400 nM gemcitabine (Selleckchem), 10 μM JPM-OEt (synthesized by the Organic Synthesis Facility at Memorial Sloan Kettering Cancer Center [MSKCC]), 50 μM to 3.2 nM ABT-263 (ApexBio), 10 μM STLC (Tocris), 2.5 μM ZM447439 (Selleckchem), 500 nM PD0325901 (Selleckchem), 500 nM MK2206 (Selleckchem), and 500 nM gefitinib (Selleckchem) were added.

Olson O.C., Kim H., Quail D.F., Foley E.A, & Joyce J.A. (2017). Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents. Cell reports, 19(1), 101-113.

+ Open protocol

+ Expand

Venetoclax Resistance in HeLa Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

HeLa, HeLa tBID2A BCL-2 cells 9 , IMR90, MRC5 and 293T cells were cultured in DMEM high-glucose medium supplemented with 10% FCS and 2 mM glutamine. CWR-R1 cells were cultured in RPMI high-glucose medium supplemented with 10% FCS and 2 mM glutamine. MRC5 and IMR90 cells were cultured in 3 % oxygen. To select for venetoclax resistant cells, HeLa tBID2A BCL-2 cells were cultured continuously in the indicated dose of venetoclax for 14 days or cultured for 8 hours in venetoclax followed by 16 hours normal medium daily. The following drugs and chemicals were used: ABT-199/venetoclax (AdooQ BioScience, A12500-50), ABT-263 (ApexBio, A3007), ABT-737 (ApexBio, A8193), Actinomycin D (Calbiochem, 114666), AZD4547 (Selleck, S2801), Chir99021 (Gift from D.

Bock F., Cloix C., Zerbst D., & Tait S.W.G. (2020). Apoptosis-induced FGF signalling promotes non-cell autonomous resistance to cell death.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!